Takeda targets global vaccine market after approval of dengue jab

Takeda has secured its first approval outside Japan for a vaccine. Photograph: Laurie Dieffembacq / AFP via Getty ImagesTakeda has said approval of its dengue fever vaccine in Indonesia marks a big step towards the company’s goal of creating a global vaccine business that would compete with larger rivals such as GSK, Sanofi and Merck.

Anticipated approvals by regulators in Europe and elsewhere would make the vaccine a key weapon in the global battle against the mosquito-borne disease that infects up to 400 million people and kills about 20,000 a year, he said. Analysts say Takeda faces a challenge to deliver on its decade-old strategy to compete with more established international rivals in the global vaccine market.

“Takeda’s policy is very clear on vaccines. It’s a step-by-step approach so they won’t take big risks to invest aggressively in everything,” said Citigroup analyst Hidemaru Yamaguchi in Tokyo. As a result, its pipeline may be slim and its expansion slow as it aims to turn a promising vaccine into a global cash cow.

ایران آخرین اخبار, ایران سرفصلها

Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.

Walmart takes Massmart private to revive South African businessRetail giant moves to gain full control ahead of expected market battle with Amazon
منبع: IrishTimesBiz - 🏆 6. / 77 ادامه مطلب »

EU preparing ‘emergency intervention’ in energy market to drive down prices‘Skyrocketing’ electricity prices are exposing limitations of current electricity market design, European Commission president says IrishTimes Vin der Leyen is the one of the most extremist politician in Europe and needs to replaced with somebody who will promote peace and a clear understanding of economies . She is a clown with a captain Ahab complex
منبع: IrishTimesBiz - 🏆 6. / 77 ادامه مطلب »